No annual revenue total was found in TECTONIC THERAPEUTIC, INC.'s SEC filings.
Tectonic Therapeutic, Inc. (TECX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$60.3 million. As of Jun 30, 2026 it held $227.1 million in cash and investments and $4.4 million in total debt.
Revenue
—
Net income (TTM)
$-85.79M
-30.0% vs year-ago TTM
Operating cash flow (TTM)
$-72.14M
-12.3% vs year-ago TTM
Free cash flow (TTM)
$-72.42M
-12.4% vs year-ago TTM
EPS (TTM)
$-4.57
-12.8% vs year-ago TTM
Dividend per share
$0.00
Shares outstanding
18.78M
+0.6% vs prior year
Net cash
$222.67M
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TECX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Watertown, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1681087
- Former names
- AvroBio, Inc. (until Jun 18, 2024); AVROBIO, Inc. (until Jun 18, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$84.0M | -$58.0M | -$44.6M | -$105.4M | -$118.8M |
| Net income | -$74.2M | -$58.0M | -$42.8M | -$105.9M | -$119.1M |
| Diluted EPS | -$4.05 | -$6.83 | -$33.76 | -$2.42 | — |
| Operating cash flow | -$60.1M | -$59.1M | -$40.7M | -$97.2M | -$98.0M |
| Free cash flow | -$60.3M | -$59.2M | -$41.0M | -$97.5M | -$100.5M |
| Total assets | $261.0M | $152.9M | $39.4M | $103.9M | $203.8M |
| Total liabilities | $9.7M | $12.1M | $43.4M | $28.6M | $34.4M |
| Stockholders' equity | $251.3M | $140.8M | -$84.6M | -$45.7M | $169.5M |
| Cash and investments | $253.8M | $141.2M | $28.8M | $92.6M | $189.6M |
| Total debt | $1.3M | $3.3M | $878,000 | $16.2M | $15.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 10, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 580 Tectonic Therapeutic, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.